Novo Holdings today announced that it has led the oversubscribed US$125 million Series C financing in Hummingbird Bioscience (Hummingbird), an innovative clinical-stage biotech company focused on developing precision therapies against difficult-to-drug targets to improve treatment outcomes. This is one of the first investments in a privately-held Asian biotech company by Novo Holdings. Novo Holdings recently established an Asian life sciences investment platform in Singapore, Novo Holdings Equity Asia Pte. Ltd

Hummingbird Bioscience, founded in 2013 is predicated on the opportunity to leverage advances in systems and computational biology to develop new treatments for cancer and other diseases

https://www.hummingbirdbioscience.com/

Copenhagen, Capital Region Of Denmark, Denmark

Novo Holdings Leads Us$125 Million Series C In Hummingbird Bioscience

Description

Company Information

Funding Insights